You are here: Industry Insights > cancer

News List

Boehringer expands oncology partnership with Oxford BioTherapeutics pharmaceutical-technology
October 16, 2020
Boehringer Ingelheim has announced the expansion of its partnership with UK-based Oxford BioTherapeutics (OBT) to discover novel selective targets for strategic cancer indications to deliver treatments for cancer patients.
FDA grants Orphan Drug Designation to two cancer treatments europeanpharmaceuticalreview
October 10, 2020
The FDA has given small molecules APG-115 and APG-1252, two cancer treatments, Orphan Drug Designation.
Charities unite to highlight pandemic’s disruption to cancer services pharmatimes
October 10, 2020
Twenty charities representing people affected by rare and less common cancers have come together to respond to and highlight the disruption caused by the COVID-19 pandemic.
Neuroblastoma UK welcomes advancement of potential new treatment pharmatimes
October 10, 2020
Neuroblastoma UK, a national research charity, has welcomed the news that a new treatment for children with neuroblastoma will be advanced into clinical trials.
Vaccibody signs agreement with Genentech for individualised neoantigen cancer vaccines pharmaceutical-technology
October 10, 2020
Biopharmaceutical company Vaccibody has signed an exclusive worldwide license and collaboration agreement with Genentech for the development and commercialisation of DNA-based individualised neoantigen cancer vaccines.
Large Study shows 230 Times Higher One Year Cancer Risk If Tumor Cell Clusters are Detected in Blood of Normal Individuals - Datar Cancer Genetics prnasia
September 30, 2020
A landmark study published in the American Association of Cancer Research's (AACR) prestigious journal 'Cancer Prevention Research' has shown that it is possible to identify healthy individuals with higher risk of cancer based on a simple blood draw.
Merck’s Keytruda plus chemotherapy meets OS and PFS goals in KEYNOTE-590 trial pharmaceutical-business-review
September 27, 2020
Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients ...
MorphoSys, I-Mab Announce IND Application Clearance for Advanced Cancer Treatment americanpharmaceuticalreview
September 27, 2020
MorphoSys and I-Mab jointly announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or ...
Gilead may soon buy Immunomedics in deal over $20 billion expresspharma
September 24, 2020
The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports.
Exelixis, NBE join forces for discovery and development of ADCs for cancer pharmaceutical-business-review
September 24, 2020
Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page